Publication date: Nov 12, 2024
Pregnant women are at increased risk for severe illness associated with coronavirus disease 2019 (COVID-19) compared to nonpregnant women. The aim of this multicenter prospective study was to assess the current COVID-19 vaccination status of pregnant women in the southern Osaka district and to compare their antibody titers with those of nonpregnant women. Serum antibody titers of anti-NCP antibodies (antibodies against the SARS-CoV-2 nucleocapsid) and anti-RBD antibodies (the receptor binding domain of the S1 subunit of the spike protein) were evaluated in 753 pregnant women at 34-35 weeks of gestation from October 2021 to March 2022. Anti-RBD antibody titre was also investigated in 1003 health care workers at Kindai University hospital 3 and 6 months after a second dose of the vaccine from March 2021 to April 2021. 519 (68. 9%) pregnant women were vaccinated during pregnancy, of whom 497 (95. 8%) received two doses. The COVID-19 infection rate calculated from the number of pregnant women with a positive anti-NCP antibody titre or with confirmed diagnosis was 5. 1% (12/234) in the unvaccinated and 3. 5% (18/519) in the vaccinated. The estimated half-life calculated from anti-RBD antibody titers and the number of days between vaccination and antibody testing was 39. 9 days. The antibody titre and half-life in pregnant women were significantly lower and shorter than in nonpregnant women aged 20-39 years (109. 4 days). Our study showed that pregnant women may have lower vaccine-acquired COVID-19 immunity than nonpregnant women.
Concepts | Keywords |
---|---|
35weeks | antibodies |
Coronavirus | coronavirus disease 2019 |
Hospital | COVID‐19 |
Osaka | pregnancy |
Pregnant | vaccination |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | coronavirus disease 2019 |
disease | IDO | protein |
disease | MESH | infection |